Letter to the Editor

Abstract

Get full access to this article

View all access options for this article.

References

Moake JL Thrombotic microangiopathies. N Engl J Med 2002; 347: 589—600.

Dold S. , Singh R. , Sarwar H. , Menon Y. , Candia L. , Espinoza LR Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome. Arthritis Rheum 2005 ; 53: 982—985.

Fakhouri F. , Vernant JP , Veyradier A. et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases . Blood 2005; 106: 1932—1937.

Franchini M. , Veneri D. , Lippi G. , Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119—125.

Gutterman LA , Kloster B. , Tsai HM Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28: 385—391.